Local application of the cannabinoid receptor agonist, WIN 55,212-2, to spinal trigeminal nucleus caudalis differentially affects nociceptive and non-nociceptive neurons

Alexander M Papanastassiou, Howard L. Fields, Ian D. Meng

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Cannabinoid receptor agonists produce analgesia for pains of non-cranial origin. However, their effectiveness for craniofacial pains is currently unclear. In the present study, the cannabinoid CB1/CB2 receptor agonist, WIN 55,212-2 (WIN), was bath applied to the brainstem while activity of spinal trigeminal nucleus caudalis (Vc) neurons evoked by transcutaneous electrical stimulation was recorded in isoflurane anesthetized rats. Neurons were characterized using mechanical and electrical stimulation of the face, and were classified as either low-threshold mechanoreceptive (LTM) or wide dynamic range (WDR). LTM neurons responded to light brushing of the receptive field and received only Aβ primary afferent fiber input. WDR neurons showed a graded response to mechanical stimulation, responding maximally to noxious stimuli, and demonstrated both A- and C-fiber evoked activity. In addition, WDR neurons displayed longer latency, C-fiber mediated post-discharge (PDC) activity after repetitive stimulation. Local bath application of 2.0 mg/ml WIN significantly reduced PDC activity (3±1% control, P<0.01), C-fiber evoked activity (58±9% control, P<0.01), and Aβ evoked activity (57±10% control, P<0.01) in WDR neurons. In contrast, LTM Aβ-fiber evoked activity increased after local administration of WIN (204±52% control, P<0.01). SR141716A, a CB1 receptor antagonist, prevented the effects of WIN on WDR PDC and LTM Aβ evoked activity. These results indicate that cannabinoid receptor agonists may be effective agents for craniofacial pain. Furthermore, the particular sensitivity of PDC activity, a measure of neuronal hyperexcitability, to cannabinoid receptor agonists may be relevant to the treatment of persistent craniofacial pain.

Original languageEnglish (US)
Pages (from-to)267-275
Number of pages9
JournalPain
Volume107
Issue number3
DOIs
StatePublished - Feb 2004
Externally publishedYes

Fingerprint

Spinal Trigeminal Nucleus
Cannabinoid Receptor Agonists
Neurons
Unmyelinated Nerve Fibers
Facial Pain
Cannabinoid Receptor CB1
rimonabant
Baths
Cannabinoid Receptor CB2
Transcutaneous Electric Nerve Stimulation
Myelinated Nerve Fibers
Isoflurane
Analgesia
Electric Stimulation
Brain Stem
Headache
Win 55212-2
Light

Keywords

  • Cannabinoid receptor agonist
  • Craniofacial pain
  • Wide dynamic range

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Neurology
  • Neuroscience(all)
  • Pharmacology
  • Clinical Psychology

Cite this

@article{80a46516ff1e4823bddff7826c1bbaa3,
title = "Local application of the cannabinoid receptor agonist, WIN 55,212-2, to spinal trigeminal nucleus caudalis differentially affects nociceptive and non-nociceptive neurons",
abstract = "Cannabinoid receptor agonists produce analgesia for pains of non-cranial origin. However, their effectiveness for craniofacial pains is currently unclear. In the present study, the cannabinoid CB1/CB2 receptor agonist, WIN 55,212-2 (WIN), was bath applied to the brainstem while activity of spinal trigeminal nucleus caudalis (Vc) neurons evoked by transcutaneous electrical stimulation was recorded in isoflurane anesthetized rats. Neurons were characterized using mechanical and electrical stimulation of the face, and were classified as either low-threshold mechanoreceptive (LTM) or wide dynamic range (WDR). LTM neurons responded to light brushing of the receptive field and received only Aβ primary afferent fiber input. WDR neurons showed a graded response to mechanical stimulation, responding maximally to noxious stimuli, and demonstrated both A- and C-fiber evoked activity. In addition, WDR neurons displayed longer latency, C-fiber mediated post-discharge (PDC) activity after repetitive stimulation. Local bath application of 2.0 mg/ml WIN significantly reduced PDC activity (3±1{\%} control, P<0.01), C-fiber evoked activity (58±9{\%} control, P<0.01), and Aβ evoked activity (57±10{\%} control, P<0.01) in WDR neurons. In contrast, LTM Aβ-fiber evoked activity increased after local administration of WIN (204±52{\%} control, P<0.01). SR141716A, a CB1 receptor antagonist, prevented the effects of WIN on WDR PDC and LTM Aβ evoked activity. These results indicate that cannabinoid receptor agonists may be effective agents for craniofacial pain. Furthermore, the particular sensitivity of PDC activity, a measure of neuronal hyperexcitability, to cannabinoid receptor agonists may be relevant to the treatment of persistent craniofacial pain.",
keywords = "Cannabinoid receptor agonist, Craniofacial pain, Wide dynamic range",
author = "Papanastassiou, {Alexander M} and Fields, {Howard L.} and Meng, {Ian D.}",
year = "2004",
month = "2",
doi = "10.1016/j.pain.2003.11.009",
language = "English (US)",
volume = "107",
pages = "267--275",
journal = "Pain",
issn = "0304-3959",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Local application of the cannabinoid receptor agonist, WIN 55,212-2, to spinal trigeminal nucleus caudalis differentially affects nociceptive and non-nociceptive neurons

AU - Papanastassiou, Alexander M

AU - Fields, Howard L.

AU - Meng, Ian D.

PY - 2004/2

Y1 - 2004/2

N2 - Cannabinoid receptor agonists produce analgesia for pains of non-cranial origin. However, their effectiveness for craniofacial pains is currently unclear. In the present study, the cannabinoid CB1/CB2 receptor agonist, WIN 55,212-2 (WIN), was bath applied to the brainstem while activity of spinal trigeminal nucleus caudalis (Vc) neurons evoked by transcutaneous electrical stimulation was recorded in isoflurane anesthetized rats. Neurons were characterized using mechanical and electrical stimulation of the face, and were classified as either low-threshold mechanoreceptive (LTM) or wide dynamic range (WDR). LTM neurons responded to light brushing of the receptive field and received only Aβ primary afferent fiber input. WDR neurons showed a graded response to mechanical stimulation, responding maximally to noxious stimuli, and demonstrated both A- and C-fiber evoked activity. In addition, WDR neurons displayed longer latency, C-fiber mediated post-discharge (PDC) activity after repetitive stimulation. Local bath application of 2.0 mg/ml WIN significantly reduced PDC activity (3±1% control, P<0.01), C-fiber evoked activity (58±9% control, P<0.01), and Aβ evoked activity (57±10% control, P<0.01) in WDR neurons. In contrast, LTM Aβ-fiber evoked activity increased after local administration of WIN (204±52% control, P<0.01). SR141716A, a CB1 receptor antagonist, prevented the effects of WIN on WDR PDC and LTM Aβ evoked activity. These results indicate that cannabinoid receptor agonists may be effective agents for craniofacial pain. Furthermore, the particular sensitivity of PDC activity, a measure of neuronal hyperexcitability, to cannabinoid receptor agonists may be relevant to the treatment of persistent craniofacial pain.

AB - Cannabinoid receptor agonists produce analgesia for pains of non-cranial origin. However, their effectiveness for craniofacial pains is currently unclear. In the present study, the cannabinoid CB1/CB2 receptor agonist, WIN 55,212-2 (WIN), was bath applied to the brainstem while activity of spinal trigeminal nucleus caudalis (Vc) neurons evoked by transcutaneous electrical stimulation was recorded in isoflurane anesthetized rats. Neurons were characterized using mechanical and electrical stimulation of the face, and were classified as either low-threshold mechanoreceptive (LTM) or wide dynamic range (WDR). LTM neurons responded to light brushing of the receptive field and received only Aβ primary afferent fiber input. WDR neurons showed a graded response to mechanical stimulation, responding maximally to noxious stimuli, and demonstrated both A- and C-fiber evoked activity. In addition, WDR neurons displayed longer latency, C-fiber mediated post-discharge (PDC) activity after repetitive stimulation. Local bath application of 2.0 mg/ml WIN significantly reduced PDC activity (3±1% control, P<0.01), C-fiber evoked activity (58±9% control, P<0.01), and Aβ evoked activity (57±10% control, P<0.01) in WDR neurons. In contrast, LTM Aβ-fiber evoked activity increased after local administration of WIN (204±52% control, P<0.01). SR141716A, a CB1 receptor antagonist, prevented the effects of WIN on WDR PDC and LTM Aβ evoked activity. These results indicate that cannabinoid receptor agonists may be effective agents for craniofacial pain. Furthermore, the particular sensitivity of PDC activity, a measure of neuronal hyperexcitability, to cannabinoid receptor agonists may be relevant to the treatment of persistent craniofacial pain.

KW - Cannabinoid receptor agonist

KW - Craniofacial pain

KW - Wide dynamic range

UR - http://www.scopus.com/inward/record.url?scp=0345829178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345829178&partnerID=8YFLogxK

U2 - 10.1016/j.pain.2003.11.009

DO - 10.1016/j.pain.2003.11.009

M3 - Article

C2 - 14736589

AN - SCOPUS:0345829178

VL - 107

SP - 267

EP - 275

JO - Pain

JF - Pain

SN - 0304-3959

IS - 3

ER -